宜明昂科生物制药（上海）申请 IMM0306 用于滤泡性淋巴瘤的中国 III 期临床试验批准（注意：公告中未提及任何资助或多个组织的参与；该新闻是关于 III 期临床试验的监管申请。）

ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. Submits Phase III Clinical Trial Application for IMM0306 in Follicular Lymphoma ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. has announced that it has submitted an application to the Center for Drug Evaluation of the National Medical Products Administration (NMPA) of China for a Phase III clinical trial of its investigational therapy, IMM0306, for the treatment of follicular lymphoma. IMM0306 is a first-in-class bispecific molecule targeting both CD47 and CD20, designed to enhance immune-mediated elimination of malignant B cells while minimizing toxicity. The company currently retains global intellectual property and commercial rights to IMM0306. No grant or funding from other organizations was mentioned in the announcement. The company cautioned that there is no guarantee of successful development or commercialization of the drug. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here